Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 10.

Journal Article

Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A. D., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann. Oncol., 29. S. 175 - 176. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Goto, K., Oxnard, G., Tan, Shao-Weng D. S. W., Loong, Ho Fung H., Bauer, T. T., Gainor, J., McCoach, C., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y., Ohe, Y., Horiike, A., Park, K., Huang, X., Olek, E., Subbiah, V, Drilon, A. and Wolf, J. (2021). Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC). Pneumologie, 75. S. S42 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Paz-Ares, L., Doebel, R. C., Farago, A. F., Liu, S., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Ye, C., Simmons, B. and Demetri, G. D. (2020). Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK-fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 74. S. S128 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. S. (2020). CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann. Oncol., 31. S. S894 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Font, E. F., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. (2021). CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation. J. Thorac. Oncol., 16 (1). S. S29 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G. K., Price, T., Borghaei, H., Kato, T., Takahashi, T., Spira, A., Ramalingam, S., Besse, B., Barlesi, F., Tran, Q., Henary, H., Ngarmchamnanrith, G., Govindan, R. and Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. Pneumologie, 75. S. S38 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

This list was generated on Thu Mar 28 18:17:29 2024 CET.